The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

Fully cell-free process aims to democratize personalized cancer therapeutics with shorter turnaround and negligible bioburden ...

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

Cervical cancer is one of the most common tumour types in women, with 14,500 new cases diagnosed every year in the US and 4,300 deaths.